Equities

CARsgen Therapeutics Holdings Ltd

CARsgen Therapeutics Holdings Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)5.88
  • Today's Change0.150 / 2.62%
  • Shares traded928.50k
  • 1 Year change-52.50%
  • Beta--
Data delayed at least 15 minutes, as of May 07 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CARsgen Therapeutics Holdings Ltd is a China-based investment holding company principally engaged in discovering, developing and commercializing innovative chimeric antigen receptor (CAR)-T cell therapies. The Company’s therapies are applied in the treatment of hematological malignancies and solid tumors. The Company have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The Company conducts its businesses in China and the United States.

  • Revenue in HKD (TTM)0.00
  • Net income in HKD-806.71m
  • Incorporated--
  • Employees516.00
  • Location
    CARsgen Therapeutics Holdings LtdBuilding 12No.388 Yindu Road, Xuhui DistrictSHANGHAI KY1-1205ChinaCHN
  • Websitehttps://www.carsgen.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
SinoMab Bioscience Ltd1.47m-262.26m2.02bn233.00--6.00--1,371.61-0.2576-0.25760.00150.30810.0015-------26.20-24.62-32.50-27.7230.92---17,810.33-4,451.74---8.150.604------14.45------
Acotec Scientific Holdings Ltd511.18m15.63m2.15bn638.00131.791.5332.764.200.0520.0521.704.460.31360.72133.44801,221.600.9589--1.03--79.65--3.06--9.122.750.1529--19.80---79.35------
Cutia Therapeutics148.47m-2.12bn2.21bn298.00--1.51--14.86-6.97-6.970.48834.79------498,206.10--------51.60---1,426.91--5.38--0.153--1,110.83---253.30------
Laekna Inc0.00-397.87m2.47bn89.00--2.84-----3.30-3.300.002.22------0.00-------------------5.280.0655------52.81------
Peijia Medical Ltd475.88m-423.45m2.49bn1.04k--1.01--5.22-0.6235-0.62350.70063.610.14730.77739.51457,576.40-13.11-34.08-14.94-36.9073.7671.62-88.99-448.756.92--0.0886--75.86--3.75------
Abbisko Cayman Ltd20.56m-465.58m2.50bn258.00--1.17--121.58-0.7194-0.71940.03183.050.0083--1.4079,696.17-18.74---19.67--100.00---2,264.34------0.0177------12.92------
MicroPort CardioFlow Medtech Corp362.70m-508.68m2.65bn592.00--1.05--7.32-0.2153-0.21530.15351.040.12052.783.67612,674.30-16.91-17.37-18.11-22.962.06-1.67-140.25-180.829.91-11.560.0293--33.94---3.77---14.16--
Frontage Holdings Corp2.03bn84.42m2.67bn1.76k32.070.9967.371.310.04090.04090.98061.320.46360.635.321,153,836.001.914.462.335.2830.1734.004.139.921.394.090.2960.003.7925.61-58.00-0.782640.43--
HighTide Therapeutics Inc0.00-593.05m2.70bn66.00--3.27-----1.25-1.25--1.60------0.00-------------------0.37980.0229-------393.76------
Golden Throat Holdings Group Co Ltd1.04bn269.87m2.75bn869.0010.191.648.822.650.3650.3651.402.260.41814.821.851,193,461.0010.8811.0015.8515.6372.5772.7926.0224.672.4834.740.2182.96-3.096.73-11.0419.61--38.94
Cryofocus Medtech Shanghai Co Ltd44.18m-105.17m3.11bn392.00--17.85--70.36-0.4398-0.43980.18480.7285------112,694.30--------75.83---258.23--4.08--0.0597--50.83--13.13------
CARsgen Therapeutics Holdings Ltd0.00-806.71m3.30bn516.00--1.70-----1.45-1.450.003.380.00----0.00-29.79---32.14----------9.54--0.0452------16.19------
China Isotope & Radiation Corp7.16bn400.19m3.49bn3.11k8.730.68993.230.4881.251.2522.3815.830.53124.221.842,305,224.006.216.5712.8213.2652.4859.8911.7012.621.73--0.191928.277.8215.35-5.432.883.632.92
Biocytogen Pharmaceuticals Beijng Co Ltd773.39m-413.12m4.10bn1.07k--4.83--5.30-1.04-1.041.942.120.273216.215.74725,509.20-14.59---18.88--70.59---53.42--1.24-21.300.4077--34.28--36.38------
CK Life Sciences Intl (Holdings) Inc5.32bn17.25m4.37bn1.93k254.191.0438.570.82160.00180.00180.55380.43590.47282.964.742,755,038.000.15321.110.2111.4330.7630.520.32412.420.85120.87960.586159.000.89360.3407-86.93-42.010.2784--
Jiangsu Recbio Technology Co Ltd0.00-617.02m4.44bn472.00--3.81-----1.28-1.280.002.410.00----0.00-25.47---30.68----------2.33--0.378------20.86------
Data as of May 07 2024. Currency figures normalised to CARsgen Therapeutics Holdings Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

11.22%Per cent of shares held by top holders
HolderShares% Held
Aegon-Industrial Fund Management Co., Ltd.as of 30 Jun 202322.98m3.99%
The Vanguard Group, Inc.as of 05 Apr 202413.96m2.43%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 20236.09m1.06%
E Fund Management Co., Ltd.as of 30 Jun 20235.79m1.01%
China Asset Management Co., Ltd.as of 30 Jun 20233.64m0.63%
GF Fund Management Co., Ltd.as of 30 Jun 20233.59m0.62%
Bosera Asset Management Co., Ltd.as of 30 Jun 20232.67m0.46%
Bank of China Investment Management Co., Ltd.as of 30 Jun 20232.60m0.45%
Fullgoal Asset Management (HK) Ltd.as of 30 Jun 20231.91m0.33%
Tian Hong Asset Management Co., Ltd.as of 30 Jun 20231.39m0.24%
More ▼
Data from 30 Jun 2023 - 02 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.